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Abstract
The main objective of the study was to assess whether augmented renal clearance was a
risk factor for mortality in a cohort of patients with Enterobacteriaceae sepsis, severe sepsis,
or septic shock that all received appropriate antimicrobial therapy within 12 hours. Using a
retrospective cohort from Barnes-Jewish Hospital, a 1,250-bed teaching hospital, we col-
lected data on individuals with Enterobacteriaceae sepsis, severe sepsis, and septic shock
who received appropriate initial antimicrobial therapy between June 2009 and December
2013. Clinical outcomes were compared according to renal clearance, as assessed by Mod-
ification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) formulas, sepsis classification, demographics, severity of illness, and
comorbidities. We identified 510 patients with Enterobacteriaceae bacteremia and sepsis,
severe sepsis, or septic shock. Sixty-seven patients (13.1%) were nonsurvivors. Aug-
mented renal clearance was uncommon (5.1% of patients by MDRD and 3.0% by CKD-EPI)
and was not associated with increased mortality. Our results are limited by the absence of
prospective determination of augmented renal clearance. However, in this small cohort,
augmented renal clearance as assessed by MDRD and CKD-EPI does not seem to be a
risk factor for mortality in patients with Enterobacteriaceae sepsis. Future studies should
assess this finding prospectively.
Introduction
Augmented renal clearance (ARC) is the term given to the phenomenon of accelerated glo-
merular filtration resulting in reduced systemic exposure to renally eliminated drugs. The inci-
dence of ARC varies by population studied, being more prevalent in persons with traumatic
injuries, persons of younger age, males, and sepsis patients with lower acute physiology and
chronic health evaluation (APACHE) II scores [1–4]. While there is no universal agreement
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on how to best measure ARC [5–9], its effect on antibiotic levels is now well established [10–
13]. Multiple studies have shown that patients with ARC have reduced exposure to renally
cleared antibiotics, but only one study has shown any effect on outcome [1, 10, 14]. We previ-
ously described a cohort of patients with Enterobacteriaceae sepsis, severe sepsis, or septic
shock that all received appropriate antibiotics within 12 hours of positive blood cultures and
found that cirrhosis, African-American race, and presence of septic shock were risk factors for
mortality [15]. As these three factors have been associated with hyperdynamic cardiac output
and thereby potentially ARC, we performed a secondary analysis of our previous cohort with
the goal of determining whether ARC was prevalent and whether it impacted mortality in a
group of patients all receiving appropriate empiric antibiotic therapy.
Materials and methods
Study location and patient population
This study was conducted at Barnes-Jewish Hospital, a 1250 bed academic medical center
located in St. Louis, MO. This was a secondary analysis of a cohort that we previously
described [15]. The study period was June 1, 2009 through December 31, 2013, corresponding
to the length of time for which an electronic medical record was available that could verify
time of antibiotic administration. All consecutive hospitalized patients with sepsis, severe sep-
sis, or septic shock and a positive blood culture for an organism in the Enterobacteriaceae fam-
ily during the study period were analyzed for eligibility. This study was approved by the
Washington University School of Medicine Human Studies Committee.
Study design and data collection
The cohort and data collection has been previously described [15]. This was a retrospective
cohort study of all patients age 18 with sepsis, severe sepsis, or septic shock (as defined by
systemic inflammatory response syndrome (SIRS) criteria) and a positive blood culture for an
organism in the Enterobacteriaceae family. Patients were included only if they had positive
blood cultures with a single organism from the Enterobacteriaceae family. ICD-9 codes indica-
tive of acute organ dysfunction or the need for vasopressors were used to classify patients as
having severe sepsis or septic shock, respectively. The primary endpoint was all-cause 30-day
mortality, calculated from the time that a positive blood culture was drawn. Only the first epi-
sode of sepsis, severe sepsis, or septic shock was evaluated. Baseline characteristics, including
age, gender, race, place of origin, healthcare exposure, receipt of antibiotics within 30 days of
positive culture, presence of immunosuppression, Acute Physiology and Chronic Health Eval-
uation (APACHE) II [16] scores (calculated based on clinical data present during the 24 hours
after positive blood cultures were drawn), Charlson Comorbidity Index, and medical comor-
bidities were obtained.
Definitions
For augmented renal clearance analysis, the highest creatinine in the 24 hours before or after
the time at which a positive blood culture was drawn was collected. Augmented renal clearance
was defined as an estimated glomerular filtration rate (GFR) of>130 mL/min/1.73 m2. All
GFRs were calculated using both the Modification of Diet in Renal Disease (MDRD) and
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas [17, 18]. We also
performed a sensitivity analysis with a GFR cutoff of 100 mL/min/1.73 m2 given prior reports
of underestimation of true GFR by the MDRD and CKD-EPI equations [5].
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All patients received appropriate initial antibiotic therapy, defined as antibiotics that had in
vitro activity against the cultured organism (and were not single-agent aminoglycosides), that
was administered within 12 hours of when a positive blood culture was drawn and continued
for at least 24 hours. Appropriateness of therapy after the initial 24 hours was not assessed. For
extended-spectrum β-lactamase producing organisms, initial use of a carbapenem was required
to be classified as appropriate treatment. Antimicrobial susceptibilities were determined using
disc diffusion methodology. Appropriate antibiotics administered 12 hours before positive
blood cultures were drawn were considered to have a time of administration of 0 minutes.
Only the first episode of bacteremia during a hospitalization was considered. Patients who
had an episode of bacteremia during their hospitalization prior to Enterobacteriaceae bacter-
emia were excluded (only two cases, one with Staphylococcus epidermidis, one with Enterococ-
cus). The following organisms were considered contaminants if not recultured within 72
hours: coagulase-negative Staphylococci, Corynebacterium, Propionibacterium acnes, or Viri-
dans group Streptococcus. Patients were excluded if they were under 18 years of age or if they
had a blood culture positive for more than one organism. All patients who did not receive anti-
biotics within 12 hours of when positive blood cultures were drawn were excluded. Discharge
on hospice was considered a mortality equivalent. All patients discharged on hospice were
considered to expire at the time of hospital discharge.
Antimicrobial monitoring
From January 2002 through the present, BJH has utilized an antibiotic control program to
help guide antimicrobial therapy for bacterial infections. During this time, the use of cefepime,
gentamicin, or vancomycin was unrestricted. However, initiation of intravenous ciprofloxacin,
imipenem, meropenem, piperacillin/tazobactam, ceftolozane/tazobactam, ceftazidime/avibac-
tam, linezolid, ceftaroline, or daptomycin was restricted and required preauthorization from
either a clinical pharmacist or infectious diseases physician. Each intensive care unit (ICU)
and non-ICU unit also had a clinical pharmacist who reviewed all antibiotic orders to insure
that dosing and interval of antibiotic administration was adequate for individual patients
based on body size, renal function, and the resuscitation status of the patient.
The initial antibiotic dosages employed for the treatment of bacterial infections at BJH are
as follows: cefepime, 1 to 2 g every 8 hours; piperacillin–tazobactam, 4.5 g every 6 hours; imi-
penem, 0.5 g every 6 hours; meropenem, 1 to 2 g every 8 hours; ceftolozane/tazobactam, 1.5 or
3 g every eight hours; ceftazidime/avibactam, 2.5 g every 8 hours; ciprofloxacin, 400 mg every
8 hours; levofloxacin, 750 mg once daily; vancomycin, 15 mg/kg every 12 hours; linezolid, 600
mg every 12 hours; and ceftaroline, 600 mg every 8 hours.
Antimicrobial susceptibility testing
The microbiology laboratory performed antimicrobial susceptibility of the bacterial isolates
using the disk diffusion method according to guidelines and breakpoints established by the
Clinical Laboratory and Standards Institute (CLSI) and published during the inclusive years of
the study [19]. All classifications of antibiotic resistance were based on in vitro susceptibility
testing using these established breakpoints. Our laboratory routinely and expeditiously adopts
updates to CLSI breakpoints. All breakpoints used for analysis in this study were those recom-
mended by the CLSI at the time cultures were drawn.
Statistical analysis
Univariate analysis was performed by chi-square or Fischer’s exact test where appropriate for
categorical values. Student’s t-test or Mann-Whitney U test was used where appropriate for
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continuous variables. Continuous variables were reported as means with standard deviations
or median with interquartile range for non-normally distributed variables. Categorical data
were expressed as frequencies. A p-value of<0.05 was considered significant. Using our previ-
ous multivariate logistic regression model [15], we attempted to force the presence of aug-
mented renal clearance into the model to determine if it changed the model. To determine risk
factors for ARC, we performed binomial logistic regression using forward selection methodol-
ogy using variables with p value of<0.10. Variables were assessed for collinearity. Goodness-
of-fit was assessed via the Hosmer-Lemeshow c-statistic. All tests were two-tailed. We also per-
formed a sensitivity analysis in which patients who received ceftriaxone were excluded, as its
clearance should not be affected significantly by renal clearance. All analysis was done using
SPSS v24 (IBM, Armonk, NY).
Results
Five-hundred ten patients with sepsis, severe sepsis, or septic shock (by SIRS criteria) due to
Enterobacteriaceae met the inclusion criteria. After exclusion of 16 patients with end-stage
renal disease, there were 494 patients for which GFR was calculated. Baseline characteristics of
the patients stratified by GFR are listed in Table 1. Augmented renal clearance was present in a
minority of patients using values obtained from MDRD (5.1%, n = 25) and CKD-EPI (3.0%,
n = 15) calculations. In univariate analysis, age, APACHE II and Charlson Comorbidity scores,
and presence of CHF or African-American race were significantly different between the ARC
and no ARC groups. Age, Charlson comorbidity and APACHE II scores were lower in patients
with ARC. African-American race was more common in the ARC group, whereas CHF was
absent. In our sensitivity analysis, we used a GFR cutoff of 100 mL/min/1.73 m2 to identify
patients with possible ARC (pARC). Using the MDRD calculation, 83 patients (16.8%) had
pARC. By CKD-EPI calculations, 82 patients (16.6%) had pARC. Table 2 provides a detailed
breakdown of GFR for the population as calculated by MDRD and CKD-EPI equations.
Seventy-three patients received two antibiotics with Gram-negative activity in the 12 hours
after positive culture and 4 received 3 antibiotics with Gram-negative activity in the 12 hours
after positive culture. The predominant Gram-negative antibiotic received was cefepime with
52.2% (n = 266) of patients receiving it within 12 hours, followed by piperacillin-tazobactam at
20% (n = 102), meropenem at 15.7% (n = 80), and ceftriaxone at 12.0% (n = 61)–see Table 3.
Patients with ARC by either MDRD or CKD-EPI calculations (n = 27) received predominantly
cefepime at 63.0% (n = 17), 14.8% (n = 4 each) received meropenem or ceftriaxone, and 11.1%
(n = 3) received piperacillin-tazobactam (Table 3). Ampicillin-sulbactam, ciprofloxacin, erta-
penem, and aztreonam were also administered to one patient each. Three patients with ARC
received 2 drugs and 1 patient received 3 drugs within 12 hours of positive blood cultures.
From our previous multivariate logistic regression analysis, sepsis severity, African-Ameri-
can race, cirrhosis, solid organ malignancy, transfer from an OSH, and APACHE-II score
were risk factors for mortality [15]. Addition of augmented renal clearance to the model did
not significantly change the model and ARC was not statistically associated with mortality (S1
Table). A GFR greater than 100 mL/min/1.73 m2 was also not associated with mortality.
Excluding patients that were discharged on hospice (n = 10, 1 with ARC) did not significantly
affect the logistic regression models for mortality or ARC.
For a sensitivity analysis, we excluded patients that received ceftriaxone as renal clearance
should not alter therapeutic efficacy. There were 61 patients that received ceftriaxone, leaving
433 available for analysis, 23 with ARC. Similarly to the entire cohort, addition of augmented
renal clearance to the model did not significantly change the model and ARC was not statisti-
cally associated with mortality (p = 0.36).
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Table 1. Patient characteristics by GFR.
Characteristics All patients without ESRD
(494)
Patients with GFR <130
(467)
Patients with GFR >130a
(27)
P valueb
Age, yrs 59.9 ± 15.8 61.0 ± 15.0 40.5 ± 16.2 <0.001
Male, % (#) 52.6 (260) 53.1 (248) 44.4 (12) 0.381
African-American, % (n) 30.0 (148) 27.8 (130) 66.7 (18) <0.001
Mechanical ventilation, % (n) 19.2 (95) 19.7 (92) 11.1 (3) 0.271
Bone marrow transplant, % (n) 4.7 (23) 4.3 (20) 11.1 (3) 0.124
Solid organ transplant, % (n) 3.8 (19) 4.1 (19) 0 0.615
CHF, % (n) 14.0 (69) 14.8 (69) 0 0.022
COPD, % (n) 14.2 (70) 14.6 (68) 7.4 (2) 0.403
Diabetes mellitus, type 2, % (n) 28.5 (141) 29.3 (137) 14.8 (4) 0.104
Solid organ malignancy, % (n) 27.9 (138) 28.7 (134) 14.8 (4) 0.118
Leukemia, % (n) 19.2 (95) 18.4 (86) 33.3 (9) 0.056
Lymphoma, % (n) 6.1 (30) 6.2 (29) 3.7 (1) 1
Cirrhosis, % (n) 5.5 (27) 5.8 (27) 0 0.387
Antibiotics within 30 days, % (n) 38.3 (189) 37.5 (175) 51.9 (14) 0.135
Healthcare exposure, % (n) 69.2 (342) 68.7 (321) 77.8 (21) 0.322
MDR, % (n) 18.6 (92) 18.8 (88) 14.8 (4) 0.8
Time to appropriate antibiotics
(hours)
2.4 [1.1–5.0] 2.4 [1.1–5] 2.1 [1.0–5.3] 0.930
Immunosuppressed, % (n) 36.8 (182) 36.6 (171) 40.7 (11) 0.666
Charlson Comorbidity Score 1.7 ± 1.3 1.7 ± 1.3 0.48 ± 0.7 <0.001
APACHE II score 13.3 ± 5.3 13.4 ± 5.3 10.2 ± 5.3 0.002
Patient origin, % (n) 0.845
Nursing home, SNF, or LTACH 8.5 (42) 8.6 (40) 7.4 (2)
Community 54.7 (270) 54.8 (256) 51.9 (14)
OSH 10.3 (51) 10.5 (49) 7.4 (2)
In hospital 26.5 (131) 26.1 (122) 33.3 (9)
Infection source, % (n)
Central venous catheter 8.9 (44) 8.8 (41) 11.1 (3) 0.724
Genitourinary 42.5 (210) 42.8 (200) 37.0 (10) 0.554
Pulmonary 5.5 (27) 5.1 (24) 11.1 (3) 0.177
Gastrointestinal 16.4 (81) 17.1 (80) 3.7 (1) 0.103
Unknown 24.5 (121) 24.0 (112) 33.3 (9) 0.272
Otherc 2.2 (11) 2.1 (10) 3.7 (1) 0.465
Sepsis 34.4 (170) 33.2 (155) 55.6 (15) 0.051 for all
categories
Severe sepsis 37.7 (186) 38.1 (178) 29.6 (8)
Septic shock 27.9 (138) 28.7 (134) 14.8 (4)
Elevated lactate (>2.1) 2.4 [1.4–4.2] 2.4 [1.4–4.2] 2.0 [1.3–3.9] 0.629
LOS 7.7 [4.7–19.6] 7.7 [4.6–19.6] 8.8 [4.8–20.8] 0.644
ICU LOS 0.8 [0–4.8] 0.9 [0–4.7] 0 [0–7.6] 0.913
Thirty-day mortality 13.0 (64) 13.1 (61) 11.1 (3) 1
aGFR >130 by MDRD or CKD-EPI.
bp value for comparison of patients with ARC to those without ARC.
cTypes of infections in the other category include central nervous system, skin and soft tissue, vascular graft, muscle, joint, osteomyelitis, and gynecologic.
ARC: augmented renal clearance. CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; ESRD: end-
stage renal disease; MDR: multi-drug resistance; APACHE II: Acute physiology and chronic health evaluation II; SNF: skilled nursing facility; LTACH: long-
term acute care hospital; OSH: outside hospital; CNS: central nervous system.
https://doi.org/10.1371/journal.pone.0180247.t001
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After multivariate logistic regression analysis, age, African-American race, and sepsis sever-
ity were found to be predictors of the presence of ARC (Table 4). The likelihood of having
ARC increased 6.4% with each decrease in year of age. Being African-American had an odds
ratio for the presence of ARC of 3.45 with 95% confidence intervals of 1.40–8.50. An increase
in sepsis severity was associated with a 36% lower likelihood of having ARC.
Discussion
We found that ARC was not a predictor of mortality among patients with Enterobacteriaceae
bloodstream infections receiving appropriate initial antimicrobial therapy within 12 hours of
positive blood cultures being drawn. Predictors of mortality in the cohort were African-Ameri-
can race, transfer from an OSH, increasing APACHE-II scores, underlying malignancy, and
cirrhosis, which are known risk factors for mortality in sepsis and reflect acute and chronic ill-
ness severity [15]. Interestingly, the percentage of patients with ARC was <5%, much lower
than reported rates in the literature [1–5, 7, 10, 20, 21]. However, ARC varies by patient popu-
lation, being more common in trauma and younger patients, which were not the predominant
demographics of our cohort. In addition, we assessed ARC retrospectively without measured
urinary creatinine clearance, which is known to underestimate the prevalence of ARC by up to
30% [5–9].
We found that African-American race, younger age, and lower sepsis severity were associ-
ated with a higher likelihood of ARC. Younger age and lower sepsis severity have previously
been shown to increase the incidence of ARC [1–4]. Although African-American race is
known to effect estimates of GFR, African-American race has not previously been reported to
increase the rate of ARC. Leukemia was more common in patients with ARC, but this was
Table 2. Proportions of patients falling into various GFR ranges as assessed by MDRD and CKD-EPI
equations.
MDRD n (%) CKD-EPI n (%)
GFR130 mL/min/1.73 m2 25 (5.1%) 15 (3.0%)
130>GFR90 mL/min/1.73 m2 92 (18.6%) 118 (23.9%)
90>GFR60 mL/min/1.73 m2 123 (24.9%) 118 (23.9%)
60>GFR30 mL/min/1.73 m2 164 (33.2%) 154 (31.2%)
30>GFR15 mL/min/1.73 m2 68 (13.8%) 65 (13.2%)
GFR <15 mL/min/1.73 m2 22 (4.5%) 24 (4.9%)
MDRD: Modification of Diet in Renal Disease. CKD-EPI: Chronic Kidney Disease Epidemiology
Collaboration. GFR: glomerular filtration rate
https://doi.org/10.1371/journal.pone.0180247.t002
Table 3. Proportions of patients receiving different antibiotics within 12 hours of positive blood culture.
All patients(510), % (n) Patients without ARC (467), % (n) Patients with ARC by MDRD or CKD-EPI (27), % (n)
Cefepime 52.2 (266) 51.2 (239) 63.0 (17)
Piperacillin-tazobactam 20.0 (102) 20.6 (96) 11.1 (3)
Meropenem 15.7 (80) 15.4 (72) 14.8 (4)
Ceftriaxone 12.0 (61) 12.0 (56) 14.8 (4)
Other 14.7 (75) 14.8 (4) 15.2 (71)
No differences between ARC and non-ARC patients were significant. Other = ampicillin, ampicillin-sulbactam, aztreonam, cefotetan, ceftaroline,
ertapenem, ciprofloxacin, doxycycline, levofloxacin, trimethoprim-sulfamethoxazole. ARC: augmented renal clearance. MDRD: Modification of Diet in Renal
Disease. CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration.
https://doi.org/10.1371/journal.pone.0180247.t003
Augmented renal clearance in Enterobacteriaceae sepsis
PLOS ONE | https://doi.org/10.1371/journal.pone.0180247 July 5, 2017 6 / 9
confounded by younger age in the ARC group with leukemia as compared to those with leuke-
mia and no ARC.
Our study is limited in several ways. The retrospective nature of the study makes it difficult
to elucidate possible confounders that could have biased the outcome measures. This was a
single-center study and results may not be generalizable to other centers. Augmented renal
clearance is difficult to definitively establish using GFR calculators rather than prospectively
collected urinary creatinine clearance measurements. In addition, beta-lactam levels are not
available at our institution, which could alter the effect of ARC on mortality if levels were sub-
therapeutic in either the ARC or non-ARC group. The use of disc diffusion methods to deter-
mine antimicrobial susceptibility is a potential limitation, as we do not have minimum
inhibitory concentrations (MIC) available to correlate with outcomes. However, previous
studies have shown good correlation between broth microdilution (BMD) and disc diffusion
[22]. In some cases, BMD techniques may misclassify resistant isolates as susceptible [23],
which would bias results towards the null. It is unknown whether misclassification of resistant
isolates as susceptible with BMD or undetected MIC differences when using disc diffusion
methodology would have a greater impact on our study conclusions. As each susceptibility
testing method has its limitations, our study provides helpful insight regarding ARC and out-
comes in the context of disc diffusion susceptibility testing. We did not study outcomes in
patients with Gram-positive infections or non-Enterobacteriaceae Gram-negative infections. It
is possible that ARC would be more important in determining clinical outcomes in popula-
tions treated with different antibiotics for other types of pathogens and this is an area ripe for
future studies. In conclusion, ARC was not a predictor of mortality in patients that all received
appropriate initial antimicrobial therapy, though the incidence of ARC in our cohort was low.
We found that African-American race, age, and sepsis severity were important predictors of
the presence of ARC. Our results provide impetus for further prospective data collection on
ARC in medical ICU populations. Future studies can assess similar outcomes in patients with
Gram-positive or Gram-negative non-Enterobacteriaceae sepsis, and determine whether ARC
is an important outcome predictor among patients receiving appropriate initial antimicrobial
therapy in those groups.
Supporting information
S1 Data. SPSS file containing data relevant for this study.
(SAV)
S1 Table. Risk factors associated with 30-day all-cause mortality, as determined by multi-
variate logistic regression. APACHE II: Acute physiology and chronic health evaluation II;
OSH: outside hospital.
(DOCX)
Table 4. Risk factors associated with ARC, as determined by multivariate logistic regression.
Factor Odds ratio [95% confidence interval]
Age 0.93 [0.91–0.96]
African-American race 3.45 [1.40–8.50]
Sepsis severity 0.54 [0.30–0.97]
African-American race and younger age significantly increased the risk for having ARC, while increasing
severity of sepsis was associated with a lower incidence of ARC.
https://doi.org/10.1371/journal.pone.0180247.t004
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